Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jhawker.... If one is taking chloroquine , one also must take a Zinc supplant with it to be effective. If taking Hydorxychloroquine, Azithromycin must be taken also. The combination of Hydorxychloroquine and azithromycin is proving to be very effective. There are doctors all around the world using the latter combination with outstanding results. And BTW Brilacidin and Hydorxychloroquine would be even better ,IMO!!!
1iftrue....That is true. No control but 80 people in French study and 79 survived.
Here is more truth:
www.sciencedirect.com/science/article/pii/S...
Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. Conclusion Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
Do not trust the Chinese stories!
Luckytouch....OK Thanks for the reply.
cpac....You can think you hit a nerve, but of what use is that to this message board. Actually that is representative of most of your offerings. Carry On.
cpac.....I used the verb form. see definition as follows: What is difference between advice and advise?
Advise is a verb meaning “to give counsel to; offer an opinion or suggestion as worth following.” Advice is a noun meaning “an opinion or recommendation offered as a guide to action, conduct, etc.”
So i advise you to learn the correct verb to use when the intent is to give counsel that is worth following.
And it is not because i want to post more. It is because i want all posts to be accurate and useful to the reader of the post.
DrBones....There was a considerable amount of Day trade short selling today by the MMs ;so those trades you saw may have been prearranged buying by the MMs to cover their shorts, and of course they were buying from their clients whom was the real sellers today.
petermantx. Thanks for your reply.
V700 ...Your advise is hurting those small investors not helping them, IMO!!!! So now just quit posting to me. I repeat you need to get up to speed on what you own.
ZROYPU....They are only testing drugs that have ALREADY been approved by the FDA for some other indication. Those that have been tested in human trials but have not been approved should be next. B should be in that group if the Govt. Labs test are satisfactory.
petemantx....How do we know BU is the lab doing the testing?
V700....Time will prove you wrong. My patience with you is about gone. The only reason we have not already had news on PO's is because of the worldwide upheaval caused by COVID19. I suppose you think that is caused by MMTIF management also???
V700....No they are not ridiculous! They are required filings by the CSE and they at times do provide new information. And this one did do just that as i have enumerated. Number 2 on my list is VERY IMPORTANT because it means a bigger market potential. SO you would do well to get up to speed on what you own or just sell and move on to what you consider a better investment.
Actually what you really should do is take advantage of the SDEL seller and buy shares to lower your average cost. That would be the sensible thing to do at this time.
What's new in this Update:
1] They [Chevron] are pursuing certain enhanced oil recovery projects
outside of North America.
2] Chevron continues to test samples from
the trials conducted in 2019. They are pursuing certain enhanced oil recovery projects
outside of North America.
3] Despite the downturn in the energy sector in 2020, we continue
to anticipate positive developments with respect to commercialization of the ARTRA
technology with Chevron as they have advised on their intent to commercialize.
4] We continue our regular weekly dialogue with Romgaz. They are moving ahead with the
issuance of a series of purchase orders as described in our MD&A report issued on
February 24, 2020
5] In January – February 2020, we engaged in discussions with two large companies, each
engaged in the oil well tracer services business. Each have expressed interest in the ARTRA technology and in the work that we have completed with Chevron and are pursuing with
Romgaz.
MY Opinnion....Positive report; so buy shares while they are depressed in price and selling at a fraction of the next 12 months cash flow per share.
MICROMEM TECHNOLOGIES INC.
MANAGEMENT’S DISCUSSION AND ANALYSIS
FOR THE THREE MONTHS ENDED JANUARY 31, 2020
PREPARED AS OF MARCH 26, 2020
3. PROJECT UPDATES:
Since the resignation of Mr. Van Fleet in August 2018, the Company has worked diligently to
establish an improved dialogue with its active strategic partners. Its management has engaged
with Chevron and Repsol as well as with its engineering and design subcontractors. It has forged
a new business relationship with Romgaz, based in Romania and has engaged with additional
engineering manufacturing and marketing resources to provide it with specialized expertise. The
Company’s CEO and CFO, under the guidance of its active board members, have assumed these
responsibilities.
Update of Product Development Activity at January 31, 2020
The current status of our active development projects is as reported below:
(a) Chevron:
We have maintained a dialogue with Chevron personnel throughout the quarter and had an
in person meeting in their Houston offices in mid-February. Our most recent
communication was via phone call on March 20th. Chevron continues to test samples from
the trials conducted in 2019. They are pursuing certain enhanced oil recovery projects
outside of North America. Despite the downturn in the energy sector in 2020, we continue
to anticipate positive developments with respect to commercialization of the ARTRA
technology with Chevron as they have advised on their intent to commercialize. Give the
current environment, the timing for such commercialization may be delayed.
(b) Romgaz:
We continue our regular weekly dialogue with Romgaz. They are moving ahead with the
issuance of a series of purchase orders as described in our MD&A report issued on
February 24, 2020 which related to our fiscal year end at October 31, 2019.
(c) Repsol S.A.:
There has been no change in the status of our dealings with Repsol from our MD&A report
filed on February 24, 2020 relating to the fiscal year ending October 31, 2019. We intend to
proceed with this project in 2020.
(d) Other:
In January – February 2020, we engaged in discussions with two large companies, each
engaged in the oil well tracer services business. Each have expressed interest in the ARTRA
13
technology and in the work that we have completed with Chevron and are pursuing with
Romgaz.
(e) We continue our discussions with Entanglement Technologies Inc. (“Entanglement”) with
respect to their participation in our go forward activity with Chevron, Romgaz and other
potential opportunities. Entanglement has developed the ARTRA technology to date
working with Micromem.
*****
OIL DEAL Breakthrough??? Exclusive: Russia calls for new enlarged OPEC deal to tackle oil demand collapse
Maria Tsvetkova, Gleb Stolyarov, Katya Golubkova
3 MIN READ
MOSCOW (Reuters) - A new OPEC+ deal to balance oil markets might be possible if other countries join in, Kirill Dmitriev, head of Russia’s sovereign wealth fund said, adding that countries should also cooperate to cushion the economic fallout from coronavirus.
FILE PHOTO: The logo of the Organisation of the Petroleum Exporting Countries (OPEC). Vienna, Austria December 6, 2019. REUTERS/Leonhard Foeger
A pact between the Organization of the Petroleum Exporting Countries and other producers, including Russia (known as OPEC+), to curb oil production to support prices fell apart earlier this month, sending global oil prices into a tailspin.
“Joint actions by countries are needed to restore the(global) economy... They (joint actions) are also possible in OPEC+ deal’s framework,” Dmitriev, head of the Russian Direct Investment Fund (RDIF), told Reuters in a phone interview.
Dmitriev and the Energy Minister Alexander Novak were Russia’s top negotiators in the production cut deal with OPEC. The existing deal expires on March 31.
“We are in contact with Saudi Arabia and a number of other countries. Based on these contacts we see that if the number of OPEC+ members will increase and other countries will join there is a possibility of a joint agreement to balance oil markets.”
Dmitriev declined to say who the new deal’s members should or could be. U.S. President Donald Trump said last week he would get involved in the oil price war between Saudi Arabia and Russia at the appropriate time.
Dmitriev also said that a global economic crisis was inevitable as global debt to the world’s gross domestic product had risen to 323% as of now from 230% at a time of the previous economic crisis of 2008. The virus just triggered it, he said.
“Efforts to restore relations between Russia and the United States are now as important as ever, we will take all the efforts our side and hope the United States will also understand that this is necessary,” he said.
The fund - the Russian Direct Investment Fund - and its partners have produced 500,000 coronavirus test kits so far, but are planning to increase production to 2.5 million kits a week.
President Vladimir Putin said on Thursday he hoped Russia would defeat coronavirus in 2-3 months, as the total number of infected Russians, including some close to the country’s elite, topped 1,000, with four virus-related deaths.
Dmitriev said he believed that Russia should follow examples of South Korea and Hong Kong - which have shown how testing can limit the coronavirus spread.
For now, the fund and its partners are focusing on producing tests for companies which need them to test workers at towns where their big plants are located, so-called single-industry or “monotowns.”
Dmitriev said that within a month, test kits for fast and mass public use would be ready, so people could order them at home via taxi and delivery service apps at tech companies Yandex (YNDX.O) and Mail.Ru (MAILRq.L). Only a third of all tests will be exported.
Reporting by Maria Tsvetkova, Gleb Stolyarov and Katya Golubkova; Editing by Andrew Osborn and Jane Merriman
Our Standards:The Thomson Reuters Trust Principles.
should have been "Invested over $200,000 in the last money raise a month or so AGO."
And yet the Fuda family continue to fund the company. Invested over $200,000 in the last money raise a month.
Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
Bin Ju, Qi Zhang, Xiangyang Ge, Ruoke Wang, Jiazhen Yu, Sisi Shan, Bing Zhou, Shuo Song, Xian Tang, Jinfang Yu, Jiwan Ge, Jun Lan, Jing Yuan, Haiyan Wang, Juanjuan Zhao, Shuye Zhang, Youchun Wang, Xuanling Shi, Lei Liu, Xinquan Wang, Zheng Zhang, View ORCID ProfileLinqi Zhang
doi: https://doi.org/10.1101/2020.03.21.990770
AbstractInfo/HistoryMetrics Preview PDF
Abstract
The pandemic caused by emerging coronavirus SARS-CoV-2 presents a serious global public health emergency in urgent need of prophylactic and therapeutic interventions. SARS CoV-2 cellular entry depends on binding between the viral Spike protein receptor-binding domain (RBD) and the angiotensin converting enzyme 2 (ACE2) target cell receptor. Here, we report on the isolation and characterization of 206 RBD-specific monoclonal antibodies (mAbs) derived from single B cells of eight SARS-CoV-2 infected individuals. These mAbs come from diverse families of antibody heavy and light chains without apparent enrichment for particular families in the repertoire. In samples from one patient selected for further analyses, we found coexistence of germline and germline divergent clones. Both clone types demonstrated impressive binding and neutralizing activity against pseudovirus and live SARS-CoV-2. However, the antibody neutralizing potency is determined by competition with ACE2 receptor for RBD binding. Surprisingly, none of the SARS CoV 2 antibodies nor the infected plasma cross-reacted with RBDs from either SARS CoV or MERS CoV although substantial plasma cross reactivity to the trimeric Spike proteins from SARS-CoV and MERS-CoV was found. These results suggest that antibody response to RBDs is viral species-specific while that cross-recognition target regions outside the RBD. The specificity and neutralizing characteristics of this plasma cross-reactivity requires further investigation. Nevertheless, the diverse and potent neutralizing antibodies identified here are promising candidates for prophylactic and therapeutic SARS-CoV-2 interventions.
Market Maker CDEL has a a willing seller at .0475 cents/share [they were the major sellers last couple of months of last year]. Difficult to tell how many shares are available, but a size order meaning a bid for 200,000 plus at .046 cents might buy some shares. Anyone who feels they are under invested in MMTIF should take advantage of this seller. In fact there are many companies that have been marked down to bargain levels for long term investors. However many of those are do not have as much upside percentage wise as MMTIF shares as they are once again selling at about 1/3 of the next 12 months cash flow per share. And the potential upside from current prices is about 30X cost. Think about that!!!!! ALL JMO!!!
Fed's Bullard: U.S. economy might see 'boom' by autumn after 'unprecedented' weakness in second quarter
Today 10:10 AM ET (MarketWatch)
St. Louis Fed President James Bullard on Wednesday said the U.S. economy could recovery strongly by the autumn. In a teleconference with reporters, Bullard said the U.S. economy will experience "unprecedented" weakness in the second quarter as the economy shuts down to protect lives. By July, there could be a "transition" time where some businesses reopen while others remain closed. By October, work could resume on projects delayed since the spring, leading to a possible "boom" period that lasts into 2021, he said. Bullard said the economy was like a car on the highway that comes upon a construction zone. The car has to slow down to navigate the twists and turns, but there is nothing inherently wrong with the engine, he said.
-Greg Robb; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
CFSTRe Annual Meeting.....Maybe June for SM....Just a guess...I hope they have some good news before the SM.
MineAllMine....No it does not mean that at all. But i only know of two neither of those are in this country. Surly there is a compound out there some where that has enough knowledge to make and sell it. And be able to answer an email answering questions from potential buyers of the product.
choosefaithseektruth.....Your best bet is to call the company. They cannot talk about anything but what has already been made public.
Also check this link for info... Scroll down to live links there: https://thecse.com/en/listings/technology/micromem-technologies-inc
Another of my opinions ....Trump will end the draconian shutdowns soon. My guess early April. And this article tells us why he will:
https://www.marketwatch.com/story/we-dont-have-enough-money-to-fix-it-trump-is-kind-of-right-about-firing-up-the-economy-real-estate-mogul-says-2020-03-24
Another opinion....Trump will end the draconian shutdowns soon. My guess early April. And this article tells us why he will:
https://www.marketwatch.com/story/we-dont-have-enough-money-to-fix-it-trump-is-kind-of-right-about-firing-up-the-economy-real-estate-mogul-says-2020-03-24
The article about Chevron reducing expenditures by $4 billion this year is causing some selling of MMTIF shares. This viewpoint is not formed on the basis of the facts about what Chevron is doing.
Chevron ,SLB, Microsoft, and Emerson are involved in establishing a robust data collection and analytics plan for early warning system on items for maintenance, repair, and sampling to SAVE money and be MORE efficient with their various operations. This work has been ongoing since the Sept. announcement of this plan among the before mentioned companies [see link below]. This plan is very comprehensive including very many different pieces of equipment across Chevron's many operations, It also includes the operation of MMTIF's AROMA units. The whole plan has to have all the parts operating efficiently to reach the optimum level of benefit. The fact that this plan exists and has been budgeted by Chevron provides comfort about the desire and commitment of Chevron to use the AROMA units because of the outstanding ROI of the units. This plan is critical in providing savings for Chevron in this time of low oil and gas prices.
ALL OF THE ABOVE IS JMO...Based on research and years of experience.
LINK:
Schlumberger, Chevron and Microsoft announce collaboration ...news.microsoft.com › 2019/09/17 › schlumberger-chevron-and-micr...
Schlumberger, Chevron and Microsoft announce collaboration to accelerate digital transformation. September 17, 2019 | Microsoft News Center
rrr1....Brilacidin!
idcc2006...It is a fact Anatabloc is an immune modulator. The former chief scientist of Rock Creek answered that question by me to him with " that is what ALL of our research shows". I wish i still gad some to continue taking, and i wish some reputable on line pharmacy would get a US source and offer it for sale.
BARDA ACTIVE.....Maybe B is next.
Inovio Pharmaceuticals (NASDAQ:INO): partnering with Ology Bioservices to manufacture INO-4800 (its DNA vaccine) for the prevention of COVID-19 infection. BARDA has provided $11.9M in funding to Ology to support the effort. Shares up 17% premarket.
Maxinvest....Those two ingested a treatment used on FISH tanks. {think about that is was to be diluted many times in the fish tank water] It was not the human version of the drug.
Chevron Cuts Spending by $4B
by Bloomberg|Kevin Crowley|Tuesday, March 24, 2020
email print
Chevron Cuts Spending by $4B
Chevron became the latest oil company to take an ax to its budget.
(Bloomberg) -- Chevron Corp. became the latest oil company to take an ax to its budget, cutting capital expenses by $4 billion and suspending its share buybacks.
Just weeks ago, Chevron Chief Executive Officer Mike Wirth pledged to keep the buyback through a downturn in oil prices. But this month’s collapse represents such a profound challenge that retaining the shareholder-friendly $5 billion a year instrument was untenable.
European rivals Royal Dutch Shell Plc and Total SA this week cut their buybacks until further notice. Exxon Mobil Corp. doesn’t have a program to buy back shares and has yet to announce any changes to its capital spending plan.
“Given the decline in commodity prices, we are taking actions expected to preserve cash, support our balance sheet strength, lower short-term production, and preserve long-term value,” Chief Executive Officer Michael Wirth said Tuesday in a statement.
The suspension of the company’s $5 billion annual share repurchase program follows buybacks of $1.75 billion of stock during the first quarter.
Chevron’s projected 2020 organic capital and exploratory spending was reduced by 20% to $16 billion. The cuts include $2 billion of expenditures in shale, primarily in the Permian Basin of West Texas and New Mexico. So-called cash capital and exploratory expenditures are seen dropping by $3.3 billion to $10.5 billion in 2020.
Production this year is seen as roughly flat relative to 2019. Permian production by the end of 2020 is expected to be about 20% below prior guidance.
To contact the reporter on this story:
Kevin Crowley in Houston at kcrowley1@bloomberg.net
To contact the editors responsible for this story:
Simon Casey at scasey4@bloomberg.net
Joe Carroll, Reg Gale
Covid 19 disrupting Drug R and D: Caught in a Covid-19 maelstrom, Eli Lilly locks down clinical trials as multibillion-dollar R&D ops derail
The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.
The pharma giant reported Monday morning that it has decided to hit the brakes on most new study starts and pause enrollment for most ongoing studies. Lilly adds that it is continuing dosing for ongoing studies, “but with study-by-study consideration.”
The pandemic has severely disrupted healthcare systems around the globe, says Lilly, making it difficult or impossible to conduct studies at many research sites. And there’s no timeline for when it expects to get back on track.
Tim Garnett
“By delaying most new study starts and pausing enrollment of new patients or healthy volunteers in most ongoing studies, we hope to ease the burden on participating healthcare facilities and allow physicians to focus more of their efforts on combating COVID-19,” said Tim Garnett, Lilly’s chief medical officer.
The implications for the R&D industry are enormous, extending to multibillion dollar CROs and a vast array of clinical support services. Lilly had expected to spend close to $6 billion this year on one of the largest drug research efforts in the world, covering an extensive pipeline that includes experimental meds for cancer, diabetes, immunology, neurodegeneration and pain.
Over the last few days, a few small biotechs have reported moves to pause studies — something that can be easier said than done. But it was clear that a vast array of clinical trials are at risk of being shelved for now — or have been shuttered already.
On Sunday Galapagos spotlighted its plans to freeze work on a slate of mid- and late-stage trials for filgotinib, a major development effort allied with Gilead, which relies on this drug as one of its key late-stage efforts.
CEO Onno van de Stolpe sent out a memo over the weekend noting:
It was decided to pause enrollment into the filgotinib trials in order to help protect patient safety. This includes the Phase 2 and Phase 3 trials of filgotinib in Crohn’s disease (DIVERSITY), the Phase 3 in psoriatic arthritis (PENGUIN), the Phase 2 trial in uveitis, and the MANTA and MANTA-RAy trials.
We anticipate the Phase 3 program in ankylosing spondylitis will now start later this year.
This does not impact the Phase 3 SELECTION program in ulcerative colitis, as this study is fully enrolled, and we still expect results in the second quarter of this year.
I want to assure you that the Galapagos team continues to face this unprecedented situation with resilience. And as challenging as the COVID-19 crisis is, this too shall pass.
On Monday, the UK biotech investor Syncona also noted that it expects the pandemic to roil clinical trial work at its companies, with delays expected to run at least 3 months. And you can expect plenty of others to follow up in a similar vein this week.
The top 15 companies in biopharma spent more than $100 billion on research last year and were on track to do that and more in 2020.
Lilly, based in Indianapolis, was one of the first of the Big Pharmas to tell staff to work from home as the industry began a slow motion train wreck in new product development and line extensions.
Social image: Eli Lilly CMO Tim Garnett via Youtube
"coronairus is an excuse to cover their failure" Seven little words that contain two errors.
1] "coronairus is an excuse"......No it is not an excuse it is real and the oil companies are dealing with a double blow ie. oil price and Covid19.
2] "their failure"...... There has not been any failure....There is a delay.
"Micromem has been advised by each partner that the respective projects are proceeding." So the delay is by the two partners meaning the project is not progressing as quickly because of the other issues that are demanding time and attention by Chevron and Romgaz.
BTW the Government of Romania is in the midst of a almost total shutdown because of Covid19.
V700...None of your post makes sense to me....Please explain it.
Micromem Provides Update
Toronto, Ontario and New York, New York--(Newsfile Corp. - March 23, 2020) - Micromem Technologies, Inc. (CSE: MRM) (OTCQB: MMTIF) ("Micromem") ("the Company") provides the following update on its current projects. Micromem has been in discussions with both Chevron and Romgaz throughout the last quarter and as recently as March 20, 2020. Micromem has been advised by each partner that the respective projects are proceeding. Micromem and both partners have agreed to adjust scheduling as a result of the COVID-19 pandemic forcing staff reductions and travel restrictions that is affecting all suppliers, manufacturers and installers.
Joseph Fuda says: "We have developed strong relationships with our partners who continue to see the value in this technology and in the installation as contemplated. The current COVID-19 Pandemic is a global tragedy and everyone's top priority is the health and safety of their employees and partners at all levels and to follow the instructions of the health officials tasked in dealing with the pandemic."
There seems to be a small seller of MMTIF at .05 cents. Buys at that price will be very profitable. JMO!!!
jvdeve....GLTY!!!
Blue Fin Trump is talking about Hydroxychloroquine.